NVP Associates’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

NVP Associates’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,077,198	Closed	-$1.32M	–	7
2023 Q3	$1.32M	Hold	3,077,198	–	–	1.18%	6
2023 Q2	$3.91M	Hold	3,077,198	–	–	3.41%	5
2023 Q1	$4.31M	Hold	3,077,198	–	–	4.96%	5
2022 Q4	$11.5M	Buy	+3,077,198	New	+$11.2M	11.26%	2

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

NVP Associates's IMPL Position: Q4 2023 in Review

NVP Associates sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 3,077,198 shares — an estimated $1.32M sold.

NVP Associates first reported a position in IMPL in Q4 2022 and held it in 4 quarters. The position peaked at $11.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

NVP Associates reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
NVP Associates sold 3,077,198 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $1.32M.
NVP Associates first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2022 and held it in 4 quarters.
NVP Associates's Impel Pharmaceuticals Inc. Common Stock position peaked at $11.5M in Q4 2022.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on NVP Associates's 13F filing for Q4 2023, filed 14 Feb 2024.